rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR L858R was more frequently harbored in the MP+ adenocarcinoma patients than in the MP- adenocarcinoma patients.
|
31732945 |
2020 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The patient was a 67-year-old male with a diagnosis of metastatic pulmonary adenocarcinoma with an L858R mutation on exon 21.
|
31371992 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Inclusion criteria were histologic diagnosis of benign nodule (control) and stage I or II adenocarcinoma harboring either p.L858R or ex</span>on19 delEGFR mutations.
|
30309763 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This case represents the first evidence that 1) bevacizumab combined with osimertinib can significantly relieve tumor growth and respiratory symptoms in non-small-cell lung cancer patients with osimertinib resistance and 2) the clinical use of osimertinib, bevacizumab, and brigatinib is effective as combination therapy for pulmonary adenocarcinoma in the presence of triple EGFR mutations of L858R, T790M, and <i>cis</i>-C797S.
|
30233215 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We enrolled consecutive patients with operable adenocarcinoma which harbored 19del or L858R to investigate the clinicopathologic characteristics and prognostic outcomes.
|
29026990 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 62-year-old Asian male never smoker who presented with stage IV EGFR L858R-positive adenocarcinoma developed EGFR T790 M mutation after 14 months of treatment with erlotinib combined with thoracic radiotherapy as first-line therapy.
|
30400855 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.
|
28625641 |
2017 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We describe here on a hitherto unreported mechanism of EGFR TKI resistance synchronously combining squamous-cell carcinoma change and occurrence of the EGFR exon 20 S768I secondary mutation in a 43 year-old woman with stage IV adenocarcinoma harbouring EGFR exon 21 L858R mutation.
|
28024692 |
2017 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We analyzed three major EGFR mutations (L858R in exon 21, E746_A750del in exon 19 and T790M in exon 20) in 80 fresh liquid cytology specimens of adenocarcinoma (ADC) or NSCLC-not otherwise specified (NOS) via the EGFR d-PCR assay and conventional real-time PCR assay using the therascreen® EGFR RGQ PCR kit (Therascreen assay).
|
27922678 |
2017 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 44-year-old male, never smoker, suffers from stage IV adenocarcinoma of the right lung with epidermal growth factor receptor (EGFR) exon-21 L858R point mutation on initial presentation.
|
28296233 |
2017 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor (EGFR) mutations (ie, exon 19 deletions and exon 21 L858R substitution) and anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers of adenocarcinoma histology, with the intent of permitting use of these predictive biomarkers to select patients who will derive maximal benefit from approved oral tyrosine kinase inhibitors (TKIs) directed against EGFR and ALK, respectively.
|
27381270 |
2016 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Advanced unresectable pulmonary adenocarcinoma with the epidermal growth factor receptor (EGFR) exon 21 L858R point mutation (Ex21) is associated with a poor prognosis.
|
27553497 |
2016 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR mutations (ex19del and L858R) were detected in 1759/8716 (20.2 %) adenocarcinomas, 28/669 (4.2 %) squamous cell carcinomas (SCC) and 8/119 (6.7 %) large cell carcinomas.
|
27259329 |
2016 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We demonstrated that adenocarcinomas with L858R mutation, rather than exon 19 deletion or wild-type EGFR gene, prefer to locate over the upper lungs.
|
26645716 |
2016 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
No significant differences in pathological stage and metastasis status were found between EGFR wild-type and mutated cases, although EGFR mutation type was related to pathological type (p=0.00) - 19-del, L858R and other mutation types respectively occurred in 34.2%, 42.5% and 23.3% of adenocarcinomas, but in 14.3%, 0% and 85.7% of non-adenocarcinomas.
|
27039821 |
2016 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although 19-deletion and L858R were the most common EGFR mutations, there was no difference of EGFR mutation in pathological subtypes of adenocarcinoma.
|
27032467 |
2016 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
IHC was performed using mutation-specific antibodies for E746-A750 deletion (DEL) and L858R point mutation (L858R) in biopsies and tissue microarrays of resected tumors from 154 patients with pulmonary adenocarcinoma.
|
25687872 |
2015 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All tumors had adenocarcinoma histology, and 20 patients (62.5 %) had an L858R mutation.
|
26003540 |
2015 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties.
|
25320360 |
2014 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Eighteen out of 20 large cell carcinomas, not otherwise specified, had glandular differentiation upon immunohistochemistry, with an exon 21 L858R EGFR mutation in one (5 %) tumor, an exon 2 KRAS mutation in eight (40 %) tumors, and an ALK translocation in one (5 %) tumor, whereas two tumors positive for CK7 and CK5/6 and negative for all other markers were considered adenocarcinoma.
|
24221342 |
2014 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the ADC/BAC group, KRAS mutations were more frequent in man (P<0.02) and EGFR mutations (exon 19 deletion and L858R) demonstrated a tendency towards worse disease-free survival (P=0.056).
|
23357969 |
2014 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We report here a case of pulmonary adenocarcinoma with concomitant EGFR mutation in exon 21 (L858R) and ALK rearrangement in naive and relapsed tumors.
|
25312989 |
2014 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In multivariate analysis, adenocarcinoma (hazard ratio, HR, 12.25; 95% CI, 37.7-41.10; p < 0.001) and major mutations (deletions in exon 19 and L858R point mutation in exon 21; HR, 2.46; 95% CI, 1.14-5.28; p = 0.022) were significant predictors of longer PFS.
|
24457318 |
2014 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Pretreatment evaluation of EGFR mutations in the resected primary adenocarcinoma specimen showed an L858R mutation in exon 21.
|
24852875 |
2014 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Seven adenocarcinoma components were EGFR mutated: five exon 19 deletions and two mutations in exon 21 (L833_V834delinsFL and L858R).Four SCLC components were EGFR mutated.
|
24457237 |
2013 |